Abstract:453 Background: More than 70% of hepatocellular carcinoma (HCC) patients are in the intermediate or advanced stages at the time of diagnosis. TACE, TKI and PD-1 antibody are all recommended for patients with unresectable HCC (uHCC) according to Chinese HCC guidelines. There are few scientific trials to back up the safety and effecacy of TACE+TKI+PD-1 antibody for the treatment of uHCC and conversion resection. In this study, we explored the safety and efficacy of the TACE+TKI+PD-1 antibody in uHCC. Methods: This is a prospective, multicenter, cohort study (NCT04997850). Key Eligibility Criteria:18 years old ≤ age ≤ 70 years old; HCC confirmed by histopathology or cytology; No systemic treatment history. ECOG PS score 0-1; Child-Pugh A/B; BCLC stage B/C.Experience group: TACE + Lenvatinib (12mg when≥ 60kg/8mg when < 60kg QD) + Camrelizumab/ Sintilimab (200 mg ivgtt Q3W);Control group: TACE. Results: From Sep 2020 to May 2021, 38 patients were enrolled in experimental group (Table). At the cutoff date (Sep 10 2021), the median follow-up was of 33.34 weeks (Table). The conversion resection rate was 50% (19/38), and the conversion success rate was 52.6% (20/38). Among the 19 patients, 5 cases achieved complete pathological response and 1 case achieved major pathological response. The 48 weeks' OS rate and PFS were 96.4% (95%CI 92.9% to 99.9%) and 91.7%(95%CI 85.8% to 97.4%).22 patients had level 3 treatment related adverse events (TRAE), there were no level 4 and 5 TRAEs. At the last follow-up, the ORR rate based on mRECIST was 84.2%, and the DCR rate was 94.7% (Table). Conclusions: TACE + Lenvatinib + PD-1 antibody is safe and effective, and conversion resection after the triple-treatment is feasible for uHCC. Clinical trial information: 04997850. Baseline characteristics, adverse events and clinical outcomes (N=38) Baseline Characteristics Gender, male, n (%) 35(92.1%) Bodyweight, kg, median, (range) 62(45-90) Etiology, [HBV/HCV/Non-HBV/HCV, n (%)] 29(76.3%)/1(2.6%)/8(21.1%) ECOG PS, [0/1, n (%)] 36(94.7%)/2(5.3%) AFP level, ng/ml, median(range) 353(0.91-470518) DCPlevel,mAU/mL,median(range) 6274(32-75000) BCLC stage, [B/C, n (%)] 9(23.7%)/29(76.3%) Tumor numbers, [1/2/3, n (%)] 19(50%)/15(39.5%)/4(10.5%) Treatment Related Adverse Events (TRAE), n (%) Any Adverse Events 100(100%) Most common TRAEs(≥50% of patients) Abdominal pain 27(71.1%) Aspartate aminotransferase increased 25(65.8%) Alanine aminotransferase increased 25(65.8%) Hypertension 22(57.9%) ≥Grade 3 TRAEs 22(57.9%) RAE leading to drug reduction 3(7.9%) TRAE leading to drug conclusions 0(0%) Clinical Outcomes mRECIST ORR 32(84.2%) CR/PR/SD/PD 6(15.8%)/26(68.4%)/4(10.5%)/2(5.3%)

Triple Combination Therapy Comprising Angiogenesis Inhibitors, Anti-Pd-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma.

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

Conversion of Initially Unresectable Hepatocellular Carcinoma (HCC) with Triple-Combination Therapy (lenvatinib, Anti-Pd-1 Antibodies, and Transarterial Therapy): A Retrospective Analysis

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor for treating unresectable hepatocellular carcinoma

Clinical Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Antibody in Treatment of Intermediate-Advanced Hepatocellular Carcinoma

Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study

Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study

The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma.

The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapies for the Treatment of Intermediate and Advanced Hepatocellular Carcinoma Unsuitable for Transarterial Chemoembolization

Efficacy of Combination Therapy with Lenvatinib, Programmed Cell Death 1 Inhibitors and Transarterial Therapy: a Propensity Score-Matching Cohort Study

Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma

Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma.

Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis

Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma

Combination Therapy with Lenvatinib and Anti-Pd-1 Antibodies for Unresectable or Advanced Hepatocellular Carcinoma: A Real-World Study.

Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high-risk: A propensity score matching study

Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.

88P Hepatic Arterial Infusion Chemotherapy (HAIC) + Lenvatinib (len) and Tislelizumab (tis) ± Transhepatic Arterial Embolization (TAE) for Unresectable Hepatocellular Carcinoma (uhcc) with Portal Vein Tumor Thrombus (PVTT) and High Tumor-Burden: A Multicenter Retrospective Study